Table 4.
Association between CXCL13 and CXCR5 tagSNPs and HIV-associated non-Hodgkin lymphoma risk
| HUGO gene name | dbSNP reference sequence number | SNP context | Genotype | Cases
|
Controls
|
ORa | 95% CI | ||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | ||||||
| CXCL13 | rs1442691 | 5′ flanking | TT | 157 | 85.8 | 471 | 89.5 | 1.00 | |
| TC | 24 | 13.1 | 52 | 9.9 | 1.23 | (0.71–2.14) | |||
| CC | 2 | 1.1 | 3 | 0.6 | 1.61 | (0.23–11.3) | |||
| CXCL13 | rs2053526 | 5′ flanking | AA | 72 | 40.0 | 195 | 37.7 | 1.00 | |
| AG | 73 | 40.6 | 219 | 42.4 | 0.86 | (0.59–1.28) | |||
| GG | 35 | 19.4 | 103 | 19.9 | 0.76 | (0.46–1.27) | |||
| CXCL13 | rs6852819 | 5′ flanking | GG | 118 | 64.5 | 348 | 66.5 | 1.00 | |
| TG | 58 | 31.7 | 156 | 29.8 | 1.07 | (0.73–1.57) | |||
| TT | 7 | 3.8 | 19 | 3.6 | 1.04 | (0.42–2.63) | |||
| CXCL13 | rs17406477 | Intron | GG | 149 | 81.9 | 430 | 81.4 | 1.00 | |
| AG | 32 | 17.6 | 94 | 17.8 | 0.93 | (0.59–1.48) | |||
| AA | 1 | 0.5 | 4 | 0.8 | 0.90 | (0.10–8.50) | |||
| CXCL13 | rs355679 | Intron | GG | 122 | 67.0 | 348 | 66.7 | 1.00 | |
| TG | 57 | 31.3 | 156 | 29.9 | 1.00 | (0.69–1.47) | |||
| TT | 3 | 1.6 | 18 | 3.4 | 0.41 | (0.12–1.46) | |||
| CXCL13 | rs2119976 | Intron | CC | 155 | 84.7 | 460 | 88.0 | 1.00 | |
| AC | 28 | 15.3 | 59 | 11.3 | 1.00 | (0.69–1.47) | |||
| AA | 0 | 0.0 | 4 | 0.8 | NE† | ||||
| CXCL13 | rs189587 | Intron | GG | 64 | 35.2 | 185 | 35.3 | 1.00 | |
| AG | 88 | 48.4 | 254 | 48.5 | 0.89 | (0.61–1.31) | |||
| AA | 30 | 16.5 | 85 | 16.2 | 0.93 | (0.55–1.59) | |||
| CXCL13 | rs355686 | Intron | CC | 111 | 60.7 | 333 | 63.4 | 1.00 | |
| TC | 67 | 36.6 | 165 | 31.4 | 1.20 | (0.83–1.73) | |||
| TT | 5 | 2.7 | 27 | 5.1 | 0.57 | (0.21–1.54) | |||
| CXCL13 | rs355689 | Intron | TT | 102 | 56.4 | 256 | 49.2 | 1.00 | |
| TC | 58 | 32.0 | 206 | 39.6 | 0.65 | (0.45–0.96) | |||
| CC | 21 | 11.6 | 58 | 11.2 | 0.84 | (0.47–1.49) | |||
| CXCL13 | rs17002733 | Intron | CC | 150 | 82.0 | 406 | 78.1 | 1.00 | |
| TC | 29 | 15.8 | 108 | 20.8 | 0.67 | (0.42–1.07) | |||
| TT | 4 | 2.2 | 6 | 1.2 | 1.48 | (0.39–5.66) | |||
| CXCL13 | rs171388 | Intron | CC | 126 | 69.2 | 348 | 65.7 | 1.00 | |
| CT | 49 | 26.9 | 166 | 31.3 | 0.74 | (0.50–1.10) | |||
| TT | 7 | 3.9 | 16 | 3.0 | 0.91 | (0.34–2.46) | |||
| CXCL13 | rs355661 | Intron | AA | 162 | 89.5 | 464 | 88.7 | 1.00 | |
| AG | 18 | 9.9 | 59 | 11.3 | 0.79 | (0.44–1.41) | |||
| GG | 1 | 0.6 | 0 | 0.0 | NEb | ||||
| CXCL13 | rs1052563 | 3′ UTR | TT | 150 | 82.4 | 414 | 78.6 | 1.00 | |
| TC | 28 | 15.4 | 108 | 20.5 | 0.66 | (0.41–1.06) | |||
| CC | 4 | 2.2 | 5 | 0.9 | 3.05 | (0.78–12.0) | |||
| CXCL13 | rs10022693 | 3′ flanking | TT | 91 | 49.7 | 233 | 46.3 | 1.00 | |
| TC | 70 | 38.3 | 206 | 41.0 | 0.79 | (0.54–1.15) | |||
| CC | 22 | 12.0 | 64 | 12.7 | 0.72 | (0.41–1.32) | |||
| CXCL13 | rs17002760 | 3′ flanking | AA | 97 | 53.6 | 282 | 54.5 | 1.00 | |
| AT | 68 | 37.6 | 198 | 38.3 | 0.92 | (0.64–1.34) | |||
| TT | 16 | 8.8 | 37 | 7.2 | 1.23 | (0.64–2.40) | |||
| CXCL13 | rs1566485 | 3′ flanking | GG | 69 | 38.3 | 165 | 32.3 | 1.00 | |
| TG | 75 | 41.7 | 242 | 47.4 | 0.69 | (0.47–1.02) | |||
| TT | 36 | 20.0 | 104 | 20.4 | 0.77 | (0.47–1.26) | |||
| CXCR5 | rs11217077 | 5′ flanking | TT | 109 | 59.6 | 309 | 59.2 | 1.00 | |
| TC | 66 | 36.1 | 190 | 36.4 | 1.03 | (0.72–1.50) | |||
| CC | 8 | 4.4 | 23 | 4.4 | 1.11 | (0.48–2.64) | |||
| CXCR5 | rs4938576 | 5′ flanking | GG | 63 | 34.8 | 163 | 31.7 | 1.00 | |
| TG | 86 | 47.5 | 267 | 51.8 | 0.75 | (0.52–1.12) | |||
| TT | 32 | 17.7 | 85 | 16.5 | 0.94 | (0.56–1.60) | |||
| CXCR5 | rs6589706 | 5′ flanking | GG | 54 | 29.8 | 150 | 28.9 | 1.00 | |
| AG | 95 | 52.5 | 263 | 50.7 | 0.98 | (0.65–1.48) | |||
| AA | 32 | 17.7 | 106 | 20.4 | 0.87 | (0.52–1.48) | |||
| CXCR5 | rs11217078 | 5′ flanking | TT | 71 | 38.8 | 220 | 42.9 | 1.00 | |
| TC | 97 | 53.0 | 240 | 46.8 | 1.25 | (0.87–1.81) | |||
| CC | 15 | 8.2 | 53 | 10.3 | 1.00 | (0.52–1.92) | |||
| CXCR5 | rs10892306 | 5′ flanking | TT | 153 | 84.5 | 454 | 87.8 | 1.00 | |
| TA | 26 | 14.4 | 60 | 11.6 | 1.09 | (0.65–1.84) | |||
| AA | 2 | 1.1 | 3 | 0.6 | 1.51 | (0.24–9.81) | |||
| CXCR5 | rs630923 | 5′ flanking | CC | 133 | 73.9 | 366 | 71.8 | 1.00 | |
| AC | 46 | 25.6 | 134 | 26.3 | 0.93 | (0.63–1.41) | |||
| AA | 1 | 0.6 | 10 | 2.0 | 0.26 | (0.04–2.12) | |||
| CXCR5 | rs10892307 | 5′ UTR | CC | 126 | 68.9 | 378 | 72.8 | 1.00 | |
| GC | 50 | 27.3 | 130 | 25.0 | 1.19 | (0.81–1.78) | |||
| GG | 7 | 3.8 | 11 | 2.1 | 2.12 | (0.77–5.84) | |||
| CXCR5 | rs523604 | Intron | AA | 43 | 24.4 | 148 | 29.7 | 1.00 | |
| AG | 92 | 52.3 | 255 | 51.2 | 1.16 | (0.76–1.79) | |||
| GG | 41 | 23.3 | 95 | 19.1 | 1.48 | (0.88–2.50) | |||
| CXCR5 | rs1623316 | Intron | CC | 74 | 41.6 | 214 | 41.8 | 1.00 | |
| GC | 73 | 41.0 | 222 | 43.4 | 0.89 | (0.61–1.31) | |||
| GG | 31 | 17.4 | 76 | 14.8 | 1.08 | (0.65–1.81) | |||
| CXCR5 | rs2230321 | SYN | CC | 172 | 94.0 | 497 | 74.3 | 1.00 | |
| TC | 11 | 6.0 | 172 | 25.7 | 1.43 | (0.63–3.29) | |||
| CXCR5 | rs3922 | 3′ UTR | TT | 57 | 31.8 | 154 | 30.0 | 1.00 | |
| TC | 91 | 50.8 | 268 | 52.2 | 0.89 | (0.61–1.33) | |||
| CC | 31 | 17.3 | 91 | 17.7 | 0.89 | (0.53–1.52) | |||
OR indicates odds ratio; CI, confidence interval
a
Adjusted for age at AIDS-NHL diagnosis in cases or reference date in controls, absolute CD4+ T cell counts from the visit closest to (and prior to) AIDS-NHL diagnosis in cases and reference date in controls, loge HIV viral RNA levels at set point, having an AIDS diagnosis prior to AIDS-NHL diagnosis or reference date, having exposure to HAART prior to AIDS-NHL diagnosis or reference date, and race/ethnicity
b
Model did not converge